Home › Compare › OXFCF vs MRK

OXFCF vs MRK: Dividend Comparison 2026

OXFCF yields 66666.67% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OXFCF wins by $8.441837856534449e+24M in total portfolio value
10 years
OXFCF
OXFCF
● Live price
66666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8.441837856534449e+24M
Annual income
$8,417,001,582,403,749,000,000,000,000,000.00
Full OXFCF calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — OXFCF vs MRK

📍 OXFCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOXFCFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OXFCF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
OXFCF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OXFCF
Annual income on $10K today (after 15% tax)
$5,666,666.67/yr
After 10yr DRIP, annual income (after tax)
$7,154,451,345,043,187,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, OXFCF beats the other by $7,154,451,345,043,187,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OXFCF + MRK for your $10,000?

OXFCF: 50%MRK: 50%
100% MRK50/50100% OXFCF
Portfolio after 10yr
$4.2209189282672247e+24M
Annual income
$4,208,500,791,201,874,400,000,000,000,000.00/yr
Blended yield
99.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

OXFCF
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OXFCF buys
0
MRK buys
0
No recent congressional trades found for OXFCF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOXFCFMRK
Forward yield66666.67% ✓3.25%
Annual dividend / share$2.00$3.08 ✓
Payout ratio50%42% ✓
1-year div growth0%5.5% ✓
5-year div CAGR0%8.2% ✓
Portfolio after 10y$8.441837856534449e+24M$30.7K ✓
Annual income after 10y$8,417,001,582,403,749,000,000,000,000,000.00 ✓$950.29
Total dividends collected$8.44020886744369e+24M ✓$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OXFCF vs MRK ($10,000, DRIP)

YearOXFCF PortfolioOXFCF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$6,677,367$6,666,666.67$11,192$351.54+$6.67M → OXFCF
2$4,167,497,846$4,160,353,063.34$12,524$392.70+$4167.49M → OXFCF
3$2,431,161,901,635$2,426,702,678,939.67$14,015$438.65+$2431161.89M → OXFCF
4$1,325,636,209,022,888$1,323,034,865,788,139.00$15,682$489.96+$1325636209.01M → OXFCF
5$675,632,775,263,916,700$674,214,344,520,262,300.00$17,547$547.23+$675632775263.90M → OXFCF
6$321,867,481,182,444,260,000$321,144,554,112,911,900,000.00$19,632$611.16+$321867481182444.25M → OXFCF
7$143,326,993,661,751,470,000,000$142,982,595,456,886,240,000,000.00$21,963$682.53+$143326993661751472.00M → OXFCF
8$59,657,925,421,851,500,000,000,000$59,504,565,538,633,426,000,000,000.00$24,571$762.18+$59657925421851500544.00M → OXFCF
9$23,211,471,150,187,795,000,000,000,000$23,147,637,169,986,416,000,000,000,000.00$27,486$851.08+$2.3211471150187796e+22M → OXFCF
10$8,441,837,856,534,450,000,000,000,000,000$8,417,001,582,403,749,000,000,000,000,000.00$30,745$950.29+$8.441837856534449e+24M → OXFCF

OXFCF vs MRK: Complete Analysis 2026

OXFCF — Stock

Velocys plc operates as a renewable fuels company. It designs, develops, and licenses its Fischer-Tropsch technology for the generation of clean, low carbon, and synthetic drop-in aviation and road transport fuel from municipal solid waste and residual woody biomass plants. It has operations in the Americas and the Asia Pacific. The company was formerly known as Oxford Catalysts Group PLC and changed its name to Velocys plc in September 2013. Velocys plc was incorporated in 2006 and is headquartered in Oxford, the United Kingdom.

Full OXFCF Calculator →

MRK — Healthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this OXFCF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OXFCF vs SCHDOXFCF vs JEPIOXFCF vs OOXFCF vs KOOXFCF vs MAINOXFCF vs JNJOXFCF vs ABBVOXFCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.